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Complex Regional Pain Syndrome (previously
known as reflex sympathetic dystrophy, RSD) is
a condition presenting with burning, non-
dermatomal pain associated with hyperhidrosis,
intermittent oedema and discolouration and with
evidence of mechanical and thermal allodynia.
Conventional treatment is with sympathetic
blockadeproduced by local anaesthetic injection
aroundtheappropriate sympathetic gangliaorby
theuse ofagents depleting the sympathetic nerve
endingsofnoradrenaline(egintravenousregional
sympathetic block with guanethidine). In a
relatively small percentage of cases treatment is
not effective. Phentolamine mesylate has been
shown to be useful in diagnosing pains with a
sympathetic component' but to date this has not
been used for treatment by the oral route for this
condition.
CASE REPORT A 32 year old male presented
with a 2 month history of burning, non-
dermatomal pain affecting the right lower leg
following a soft tissue injury precipitated by a
fall.Inadditiontopainhehadintermittentoedema,
bluediscolouration,hyperhidrosisandmechanical
andthermalallodynia. Radiographicexamination
failed to reveal any abnormality. Simple
analgesics failed to control his pain but it was
completely although temporarily relieved for 48
hours by an intravenous bolus of 15 mg
phentolamine mesylate. A diagnosis ofcomplex
regionalpainsyndrometype 1 (atthattimeknown
as reflex sympathetic dystrophy) was made.
Subsequently a lumbar sympathectomy using
phenolwasperformedunderradiographiccontrol.
This relieved the discomfort for 6 weeks. When
the pain returned it was not amenable to non-
steroidal or simple analgesics and indeed repeat
chemical lumbar sympathectomy produced no
relief. This patient attended the clinic every 3
days and was given phentolamine mesylate 20
mg intravenously whichrelievedpain for 2 days.
After 10 months of intravenous therapy as
described a dose of 20 mg phentolamine was
given orally on a daily basis (the content of the
ampoule was emptied into a glass ofwater). This
gave consistent pain reliefover a 24 hourperiod.
The regime has been maintained for the three
month period leading up to this report.
Despite its effect on peripheral alpha receptors,
treatment with short acting alpha antagonist
phentolamine mesylate is not associated with
significant hypotension or reflex tachycardia.2
Orally active alpha antagonists are available
(forexamplephenoxybenzamine) butthese seem
to be less active against sympathetically
maintained pain and have a greater hypotensive
effect. Oraluseofphentolamineisnotappropriate
as a routine treatment, but may be useful in the
diagnosis and the treatment ofthe small group of
patients in whom conventional treatment is
unsuccessful but who are responsive to
phentolamine. Phentolamine mesylate has been
usedorally inthosewitherectileimpotence3' 4but
has notbeendescribedbeforeforthetreatmentof
those with complex regional pain syndrome.
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